Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies

Inclusion Criteria:

* Age \>18 years;
* Histologically confirmed diagnosis of a CD20+ B-cell malignancy;
* Received at least one prior treatment regimen;historically documented CD20-positivity is acceptable;
* Appropriate for single agent study drug therapy as prescribed by this protocol;
* ECOG performance status 0 to 2;
* Adequate hematopoietic, renal, and hepatic functions defined as:

  * Absolute neutrophil count greater than 1000 /mm³
  * Platelet count greater than 75,000/mm³
  * Hemoglobin greater than 8.5 g/dL
  * Serum creatinine ≤ 1.5x upper limit of normal
  * AST, ALT, and total bilirubin ≤ 3x upper limit of normal;
* Ability to understand and the willingness to sign a written informed consent document;
* Life expectancy of 6 months or greater.

Exclusion Criteria:

* Anti-CD20 therapy within 4 weeks of enrollment;
* Systemic chemotherapy or immunotherapy within 14 days of enrollment;
* Chronic systemic steroid therapy defined as prednisone or equivalent 10 mg/day or greater;
* Systemic cytotoxic or immunosuppressive therapy to be administered concomitantly while participating on this study;
* Active infection, chronic or severe infection requiring ongoing antimicrobial therapy.
* Positivity for hepatitis B (defined as HepBs Antigen +), hepatitis C (defined as HepC Antibody +), or HIV; HIV positive patients on antiretroviral therapy will be excluded;
* History of allergic reactions attributed to compounds of similar chemical or biologic composition;
* Significant cardiac disease (New York Heart Association classes III or IV) or unstable angina despite medication;
* Women who are pregnant or breast-feeding;
* Women of child bearing potential who are unwilling to use effective contraception for the duration of the study drug administration and 6 months after final dose of drug is administered;
* Psychiatric illness/social situations that would limit compliance with study requirements;
* Participation in other investigational studies while enrolled on this trial.